---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-020296"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T12:56:57.107337+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents postpones Q4/FY2024 earnings to March 25 after controller's death; reaffirms prelim revenue

## Summary
- Q4 product revenue expected $9.0-9.2M (22-25% YoY growth); full-year $35.4-35.6M (~14% growth).
- Q4 product gross margin ~70%, vs 61% prior quarter and 72% Q4 2023.
- Pro-forma cash balance Dec 31, 2024 ~$17.0M (incl. $7.3M net from rights offering/warrants); Q4 cash burn ~$2.5M.
- DrugSorb-ATR marketing applications under substantive review with FDA and Health Canada; decisions expected in 2025.
- Delay due to unexpected passing of VP and Corporate Controller James E. Cason, Jr.; earnings call rescheduled to March 25.

## SEC filing metadata
- accession: 0001104659-25-020296
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465925020296/0001104659-25-020296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465925020296/tm258215d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-020296
- JSON: https://secwatch.observer/filing/0001104659-25-020296.json
- Plain text: https://secwatch.observer/filing/0001104659-25-020296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.